AU2006274685A1 - Artificial platelets - Google Patents

Artificial platelets Download PDF

Info

Publication number
AU2006274685A1
AU2006274685A1 AU2006274685A AU2006274685A AU2006274685A1 AU 2006274685 A1 AU2006274685 A1 AU 2006274685A1 AU 2006274685 A AU2006274685 A AU 2006274685A AU 2006274685 A AU2006274685 A AU 2006274685A AU 2006274685 A1 AU2006274685 A1 AU 2006274685A1
Authority
AU
Australia
Prior art keywords
peptide
fibrinogen
fibrinogen binding
binding
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006274685A
Other languages
English (en)
Inventor
Alison Helena Goodall
Sarah Margaret Taylor
Greg Francis Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haemostatix Ltd
Original Assignee
Haemostatix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haemostatix Ltd filed Critical Haemostatix Ltd
Publication of AU2006274685A1 publication Critical patent/AU2006274685A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2006274685A 2005-08-04 2006-08-04 Artificial platelets Abandoned AU2006274685A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0516091.6 2005-08-04
GBGB0516091.6A GB0516091D0 (en) 2005-08-04 2005-08-04 Therapeutic agent
PCT/GB2006/002934 WO2007015107A2 (en) 2005-08-04 2006-08-04 Artificial platelets

Publications (1)

Publication Number Publication Date
AU2006274685A1 true AU2006274685A1 (en) 2007-02-08

Family

ID=34984119

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006274685A Abandoned AU2006274685A1 (en) 2005-08-04 2006-08-04 Artificial platelets

Country Status (9)

Country Link
US (2) US20090203619A1 (enExample)
EP (2) EP2335737A3 (enExample)
JP (1) JP2009505964A (enExample)
CN (1) CN101267843A (enExample)
AU (1) AU2006274685A1 (enExample)
CA (1) CA2625917A1 (enExample)
GB (2) GB0516091D0 (enExample)
IL (1) IL189105A0 (enExample)
WO (1) WO2007015107A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623607D0 (en) 2006-11-27 2007-01-03 Haemostatix Ltd Tissue adhesive
EP2120989A1 (en) * 2007-03-21 2009-11-25 DSM IP Assets B.V. Cholesterol lowering protein hydrolysates
KR20100061487A (ko) * 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 펩티드 ｙｇｌｆ 및 ｋｖｌｐｖｐｑ와의 배합물의 치료적 용도
KR20100057641A (ko) * 2007-09-11 2010-05-31 몬도바이오테크 래보래토리즈 아게 인터메딘 ４７ 및 ５３ 펩티드의 치료적 용도
GB201101740D0 (en) * 2011-02-01 2011-03-16 Haemostatix Ltd Therapeutic agents with improved fibrinogen binding
WO2013021353A1 (en) * 2011-08-11 2013-02-14 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
GB201201751D0 (en) * 2012-02-01 2012-03-14 Haemostatix Ltd Haemostatic wound dressing
US20140364368A1 (en) * 2013-06-06 2014-12-11 Massachusetts Institute Of Technology Stimulus responsive nanocomplexes and methods of use thereof
WO2014210558A1 (en) * 2013-06-28 2014-12-31 Biogen Idec Ma Inc. Thrombin cleavable linker with xten and its uses thereof
WO2015073418A2 (en) * 2013-11-15 2015-05-21 President And Fellows Of Harvard College Methods and assays for factor viii activity
GB201400292D0 (en) * 2014-01-08 2014-02-26 Haemostatix Ltd Peptide dendrimers and agents
DK3091997T5 (da) 2014-01-10 2024-10-14 Bioverativ Therapeutics Inc Kimære faktor viii-proteiner og anvendelser deraf
GB201508024D0 (en) * 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions
CN107686506B (zh) * 2016-08-05 2021-03-30 首都医科大学 华法林-4-o-乙酰-gprp,其合成,活性和应用
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
CN108976284B (zh) * 2017-05-31 2021-11-30 首都医科大学 含Gly-Pro-Arg-Pro的五肽修饰的华法林,其合成,活性和应用
CN108976285B (zh) * 2017-05-31 2021-11-30 首都医科大学 Gly-Pro-Arg-Pro-AA修饰的华法林,其合成,活性和应用
EP3618853B1 (en) * 2018-04-24 2020-09-09 Fibriant B.V. Fibrinogen gamma prime variants for use in treating an infection
RS66972B1 (sr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Metode lečenja hemofilije a
CN115010784B (zh) * 2022-05-16 2023-03-31 江南大学 一种ace抑制肽及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925331A (en) * 1992-05-21 1999-07-20 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
GB9107628D0 (en) 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
US6184205B1 (en) * 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
AU3719395A (en) * 1994-09-21 1996-04-09 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
EP1028752B1 (en) * 1996-10-21 2004-12-15 Quadrant Drug Delivery Limited Platelet substitutes and conjugation methods suitable for their preparation
WO1998055105A1 (en) * 1997-06-05 1998-12-10 Hemosphere, Inc. Fibrinogen-coated microspheres
DK9700423U3 (da) * 1997-11-10 1999-03-12 Simatek A S Multifunktion cip-dyse
CA2320219A1 (en) * 1998-02-20 1999-08-26 Quadrant Healthcare (Uk) Limited Products comprising fibrinogen for use in therapy
GB9827813D0 (en) * 1998-12-17 1999-02-10 Andaris Ltd Pharmaceutical conjugates
US6984373B2 (en) * 2000-12-23 2006-01-10 Dyax Corp. Fibrin binding moieties useful as imaging agents
GB0323378D0 (en) * 2003-10-07 2003-11-05 Univ Leicester Therapeutic agent
GB0413346D0 (en) * 2004-06-15 2004-07-21 Theryte Ltd Treating cancer
GB201201751D0 (en) * 2012-02-01 2012-03-14 Haemostatix Ltd Haemostatic wound dressing

Also Published As

Publication number Publication date
US20090203619A1 (en) 2009-08-13
EP2335737A2 (en) 2011-06-22
US20130029913A1 (en) 2013-01-31
WO2007015107A3 (en) 2007-07-26
GB0516091D0 (en) 2005-09-14
GB2429153C (en) 2019-01-23
GB0615545D0 (en) 2006-09-13
CN101267843A (zh) 2008-09-17
IL189105A0 (en) 2008-08-07
CA2625917A1 (en) 2007-02-08
GB2429153B (en) 2010-03-10
EP2335737A3 (en) 2013-09-25
WO2007015107A2 (en) 2007-02-08
JP2009505964A (ja) 2009-02-12
GB2429153A (en) 2007-02-21
EP1919508B1 (en) 2015-02-25
EP1919508A2 (en) 2008-05-14

Similar Documents

Publication Publication Date Title
US20130029913A1 (en) Artificial platelets
RU2503464C2 (ru) Биогель
Pawlowski et al. Platelet microparticle-inspired clot-responsive nanomedicine for targeted fibrinolysis
AU2004280115B2 (en) Fibrinogen targetting microparticles for promoting haemostasis
US20110077202A1 (en) Targeted Coagulation Factors and Method of Using the Same
US9724379B2 (en) Therapeutic agents with improved fibrinogen binding
JP2007507480A5 (enExample)
Zhang et al. Thrombin and Thrombin‐Incorporated Biomaterials for Disease Treatments
WO2008121721A2 (en) Targeted delivery and expression of procoagulant hemostatic activity
RU2709738C1 (ru) Композиции для инъекций на основе коллагена, способные контролировать кровотечение и/или замещать тромбоциты при геморрагических синдромах
KR20050111583A (ko) 펩티드 결합체
CN100360554C (zh) 肽缀合物
Alam et al. Platelet substitutes
Sun Clot-Targeted Enzyme-Responsive Nanoparticles for Thrombolytic Therapy
WO2000035487A1 (en) Pharmaceutical conjugates comprising two active agents
MXPA99003677A (en) Platelet substitutes and conjugation methods suitable for their preparation

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period